Vericel (VCEL) Non-Current Deffered Revenue (2016 - 2019)
Vericel's (VCEL) quarterly Non-Current Deffered Revenue came in at $1.9 million in Q2 2019, down 3.01% year-over-year from $2.0 million in Q2 2018, and little changed quarter-over-quarter from $1.9 million in Q1 2019.
Analysis
Vericel (VCEL) Non-Current Deffered Revenue (2016 - 2019) Analysis & Trends
Vericel has disclosed Non-Current Deffered Revenue across 4 years of filings, most recently posting $1.9 million for Q2 2019.
- In Q2 2019, Non-Current Deffered Revenue fell 3.01% year-over-year to $1.9 million; the TTM figure through Jun 2019 stood at $1.9 million (down 3.01% YoY), while the FY2018 annual figure was $1.7 million, down 19.09% from the prior year.
- Non-Current Deffered Revenue came in at $1.9 million for Q2 2019 at Vericel, roughly flat from $1.9 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $2.1 million in Q4 2017 to a low of $900000.0 in Q2 2016.
- Average Non-Current Deffered Revenue over 4 years is $1.7 million, with a median of $1.7 million recorded in 2016.
- Year-over-year, Non-Current Deffered Revenue surged 74.11% in 2017 and fell 19.09% in 2018.
- Over 4 years, Non-Current Deffered Revenue stood at $1.7 million in 2016, then gained by 22.05% to $2.1 million in 2017, then declined by 19.09% to $1.7 million in 2018, then increased by 14.05% to $1.9 million in 2019.
- Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $1.9 million in Q2 2019, $1.9 million in Q1 2019, and $1.7 million in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.26 Bn | 9.41 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.20 Bn | 5.20 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | - |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | - |
| 5 | uniQure | 3.06 Bn | 3.06 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.68 Bn | 2.68 Bn | - | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.34 Bn | 1.55 Bn | 251.87 Mn | 110.13 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | - |
| 10 | Taysha Gene Therapies | 1.99 Bn | 1.99 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2019 | 1.90 Mn |
| Mar 31, 2019 | 1.90 Mn |
| Dec 31, 2018 | 1.67 Mn |
| Sep 30, 2018 | 1.90 Mn |
| Jun 30, 2018 | 1.96 Mn |
| Mar 31, 2018 | 1.95 Mn |
| Dec 31, 2017 | 2.06 Mn |
| Sep 30, 2017 | 1.61 Mn |
| Jun 30, 2017 | 1.57 Mn |
| Mar 31, 2017 | 1.63 Mn |
| Dec 31, 2016 | 1.69 Mn |
| Sep 30, 2016 | 1.23 Mn |
| Jun 30, 2016 | 900,000.00 |